Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discusses phase III findings from the IPATential150 trial, which showed the effectiveness of ipatasertib plus abiraterone as first-line treatment in patients with metastatic castration-resistant prostate cancer vs placebo plus abiraterone. Analyses of biomarkers linked to the PI3K/AKT pathway, a subtype with a poor prognosis, further support this therapeutic option (Abstract 13).
Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, discusses phase III results from the EV-301 trial, which showed that enfortumab vedotin is the first therapy to de...
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results of the CLEAR study, which showed that for first-line treatment of advanced renal cell carci...
Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses final results of the phase III TITAN study, which showed apalutamide plus androgen-depri...
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses key abstracts discussed at this year’s meeting on renal cell carcinoma and offers her views on the latest tren...
Tracy L. Rose, MD, of the University of North Carolina at Chapel Hill, discusses phase II results of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant th...